Sofinnova Promotes Javier Nunez-Vicandi to Partner in Digital Medicine Push

Sofinnova Partners, a Paris-based venture capital firm managing over €4 billion in assets, has promoted Javier Nunez-Vicandi to Partner, expanding its Digital Medicine team to three partners. The move signals how firmly the 54-year-old firm has anchored AI to its investment identity.

Nunez-Vicandi joins Edward Kliphuis and Simon Turner in the Digital Medicine strategy, which backs startups at the intersection of biology, data and AI. Since arriving in 2022, he has shaped the strategy's core AI investment theses and holds board observer seats at five portfolio companies: Latent Labs, Bioptimus, Cure51, Deepc and Kiro. He has also recently led one investment that remains in stealth.

In plain terms: the firm has handed a partner title to the person who built much of its AI playbook.

What else does Nunez-Vicandi run at Sofinnova?

Beyond deal work, he co-led the project that created Sofia, the firm's proprietary AI platform used to support investment decisions and scientific analysis. That effort produced collaborations with two of the largest names in computing infrastructure: AWS and NVIDIA.

The announcement, however, offers no figures on Sofia's performance, no deal sizes and no valuation details on the stealth investment. What the release does make clear is that Sofinnova treats internal AI tooling as a competitive asset, not a side project.

The takeaway: Sofinnova now sells AI capability to founders while also consuming it in-house.

What does the Digital Medicine strategy actually invest in?

The strategy splits into two lanes. Healthtech applies technology to healthcare delivery. Techbio puts AI and other computational techniques to work in biological research and drug discovery.

Chairman and Managing Partner Antoine Papiernik framed the promotion in personal terms. "Javier combines clinical experience, scientific rigor and a deep understanding of technology," Papiernik said. "Since joining the firm, he has become a trusted investor, a valued colleague and an important contributor to our Digital Medicine strategy. We are delighted to welcome him to the partnership."

Nunez-Vicandi himself pointed to his medical background as motivation. "My time seeing patients showed me just how critical getting treatments that work to the people that need them can be," he said. "It is a privilege to support world-class founders using AI to create a world of healthcare abundance at Sofinnova and I am excited to take on this new role."

The rhetoric promises healthcare "abundance"; the release does not quantify what the Digital Medicine strategy has returned so far. That gap leaves the strategy's financial track record untested in public view.

Where did Nunez-Vicandi come from?

His CV reads as a deliberate bridge between medicine and venture capital. He began as a practicing physician at Oxford University Hospitals NHS Foundation Trust, including roles at the National Spinal Injuries Centre and Churchill Hospital.

He then moved to M Ventures as an analyst covering data-driven healthcare, biotechnology and automation. From there he became the first employee at Heal Capital, an early-stage healthtech fund, where he helped grow the portfolio from launch to 12 investments.

His academic credentials include an MPhil with distinction from the University of Cambridge and a Bachelor of Medicine, Bachelor of Surgery (MBBS) from Newcastle University.

In short: a clinician-turned-investor with a decade-spanning path from hospital wards to term sheets.

How big is the platform behind the promotion?

Sofinnova Partners, founded in 1972, operates from Paris, London and Milan. The firm describes itself as a hands-on company builder across the full life-sciences value chain, from seed to later-stage, specializing in healthcare and sustainability.

Its numbers carry weight: more than 50 years of activity and over 500 companies backed, with assets under management above €4 billion — roughly the scale of a mid-tier European buyout fund, concentrated entirely in life sciences.

The promotion gives the Digital Medicine strategy three partners at a moment when AI-heavy biotech founders can choose among well-capitalized backers across Europe and the US. Whether Sofinnova's clinician-led, platform-equipped approach wins those deals is the question the next fund's returns will answer.